Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-03

AUTHORS

M. Reni, S. Cereda, E. Bonetto, M. G. Viganò, P. Passoni, A. Zerbi, G. Balzano, R. Nicoletti, C. Staudacher, V. Di Carlo

ABSTRACT

BACKGROUND: PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial. This regimen was subsequently modified in a dose-finding study by increasing dose intensity of cisplatin and epirubicin (both at 30 mg/m2 every 14 days) and of gemcitabine (at 800 mg/m2 every 14 days). Results of a consecutive series treated by dose-intense PEFG regimen are herewith reported. MATERIAL AND METHODS: Dose-intense PEFG was administered to chemotherapy-naive patients with stages III-IV PA, < 75 years, performance status (PS) > 50, till progressive disease or for a maximum of 6 months. RESULTS: Between January 2004 and June 2005, 49 (31 or 63% metastatic) patients, median age 62 years, median PS 80, were treated with dose-intense PEFG. Partial response and stable disease was observed in 24 (49%) and 16 (33%) patients, respectively; 31 patients were progression-free at 6 months (PFS-6 = 63%). Median survival was 10.5 months and 1-year overall survival (OS) was 48% (95% confidence interval: 33-61%). Main grade 3-4 toxicity was: neutropenia in 26% of patients, stomatitis and fatigue in 8%, anaemia, diarrhoea, nausea/vomit in 6%, febrile neutropenia and thrombocytopaenia in 4%, hand-foot syndrome in 2%. CONCLUSION: When compared with 84 patients treated by classical PEFG at the same institution, dose-intense PEFG was not inferior in terms of PFS-6 (63 versus 57%), 1-year OS (48 versus 42%) and response rate (49 versus 49%); it allowed to increase dose intensity for gemcitabine by 32%, for cisplatin and epirubicin by 36% (FU reduced by 3%), to significantly reduce grade 3-4 hematological toxicity (neutropenia: 26 versus 86%; P < 0.00001; thrombocytopaenia: 4 versus 58%; P < 0.00001) and to reduce by one-third the number of outpatient accesses. The new PEFG schedule appears more suitable for clinical use and should be preferred as a basis for further development of therapeutic strategies against pancreatic cancer. More... »

PAGES

361

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-006-0277-7

DOI

http://dx.doi.org/10.1007/s00280-006-0277-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040836963

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16807732


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epirubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reni", 
        "givenName": "M.", 
        "id": "sg:person.01164712517.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164712517.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cereda", 
        "givenName": "S.", 
        "id": "sg:person.01210713123.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210713123.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bonetto", 
        "givenName": "E.", 
        "id": "sg:person.0653211100.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653211100.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vigan\u00f2", 
        "givenName": "M. G.", 
        "id": "sg:person.014206563142.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014206563142.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Passoni", 
        "givenName": "P.", 
        "id": "sg:person.01134654171.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134654171.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Surgery, San Raffaele Scientific Institute, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zerbi", 
        "givenName": "A.", 
        "id": "sg:person.0736672032.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736672032.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Surgery, San Raffaele Scientific Institute, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Balzano", 
        "givenName": "G.", 
        "id": "sg:person.01301141117.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301141117.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Radiology, San Raffaele Scientific Institute, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nicoletti", 
        "givenName": "R.", 
        "id": "sg:person.01106712025.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106712025.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Surgery, San Raffaele Scientific Institute, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Staudacher", 
        "givenName": "C.", 
        "id": "sg:person.0635165414.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635165414.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "San Raffaele Hospital", 
          "id": "https://www.grid.ac/institutes/grid.18887.3e", 
          "name": [
            "Department of Surgery, San Raffaele Scientific Institute, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Di Carlo", 
        "givenName": "V.", 
        "id": "sg:person.0613402062.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613402062.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1159/000227250", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002795994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1996.241", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008202113", 
          "https://doi.org/10.1038/bjc.1996.241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1996.241", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008202113", 
          "https://doi.org/10.1038/bjc.1996.241"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdf197", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014876436"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000086780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016938291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000086780", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016938291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000094563", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018012713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.10.112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020324460"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.12.082", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022163283"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi309", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024868281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdi309", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024868281"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(05)70175-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026335507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/07357909009017560", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031573606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600446", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036077984", 
          "https://doi.org/10.1038/sj.bjc.6600446"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600446", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036077984", 
          "https://doi.org/10.1038/sj.bjc.6600446"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19910715)68:2<264::aid-cncr2820680208>3.0.co;2-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039599345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(93)90175-f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042821579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6690600", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045839896", 
          "https://doi.org/10.1038/sj.bjc.6690600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6690600", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045839896", 
          "https://doi.org/10.1038/sj.bjc.6690600"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(85)90172-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047008979"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.06.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048830818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1026595525977", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056311729"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/4.suppl_2.s21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059393332"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.09.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203121"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.11.149", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203191"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.02.098", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.03.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203433"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.2.585", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074265658"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.10.2679", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074814012"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.15.3447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074857555"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a058495", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082841549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.annonc.a059319", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082871349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.6.2403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083106816"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-03", 
    "datePublishedReg": "2007-03-01", 
    "description": "BACKGROUND: PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial. This regimen was subsequently modified in a dose-finding study by increasing dose intensity of cisplatin and epirubicin (both at 30 mg/m2 every 14 days) and of gemcitabine (at 800 mg/m2 every 14 days). Results of a consecutive series treated by dose-intense PEFG regimen are herewith reported.\nMATERIAL AND METHODS: Dose-intense PEFG was administered to chemotherapy-naive patients with stages III-IV PA, < 75 years, performance status (PS) > 50, till progressive disease or for a maximum of 6 months.\nRESULTS: Between January 2004 and June 2005, 49 (31 or 63% metastatic) patients, median age 62 years, median PS 80, were treated with dose-intense PEFG. Partial response and stable disease was observed in 24 (49%) and 16 (33%) patients, respectively; 31 patients were progression-free at 6 months (PFS-6 = 63%). Median survival was 10.5 months and 1-year overall survival (OS) was 48% (95% confidence interval: 33-61%). Main grade 3-4 toxicity was: neutropenia in 26% of patients, stomatitis and fatigue in 8%, anaemia, diarrhoea, nausea/vomit in 6%, febrile neutropenia and thrombocytopaenia in 4%, hand-foot syndrome in 2%.\nCONCLUSION: When compared with 84 patients treated by classical PEFG at the same institution, dose-intense PEFG was not inferior in terms of PFS-6 (63 versus 57%), 1-year OS (48 versus 42%) and response rate (49 versus 49%); it allowed to increase dose intensity for gemcitabine by 32%, for cisplatin and epirubicin by 36% (FU reduced by 3%), to significantly reduce grade 3-4 hematological toxicity (neutropenia: 26 versus 86%; P < 0.00001; thrombocytopaenia: 4 versus 58%; P < 0.00001) and to reduce by one-third the number of outpatient accesses. The new PEFG schedule appears more suitable for clinical use and should be preferred as a basis for further development of therapeutic strategies against pancreatic cancer.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00280-006-0277-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "59"
      }
    ], 
    "name": "Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma", 
    "pagination": "361", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c2881d6f31213e0428f2a9c92a0a134ef8c85ad6db4e9e21b0490103ad63a28c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16807732"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-006-0277-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040836963"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-006-0277-7", 
      "https://app.dimensions.ai/details/publication/pub.1040836963"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13081_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00280-006-0277-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0277-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0277-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0277-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-006-0277-7'


 

This table displays all metadata directly associated to this object as RDF triples.

288 TRIPLES      21 PREDICATES      74 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-006-0277-7 schema:about N35bc1b10fc4249b7890a360a025d7ab6
2 N3b8c4fc0d0cd4aa2aaef9187cbfb149d
3 N4494ff0f18c74dac90bf1f8d1da88352
4 N4dd4a4262e1d44f785c0c57bc11cad05
5 N60549f56ff20416086a684d7c21af644
6 N700472d67897436ab8f2fe79e19a179f
7 N7d75d175f19645d28da64e8eb2c69326
8 N948a80440f7a48969383599720c58afa
9 Na1ef3444a42247f0900f27af05b6a273
10 Nbc92367c1544482fa38207f0c184da14
11 Nd5b0e4910db64270b901219620839a59
12 Ndd38beb575484bb0937f7522aeb3b06e
13 Ndebe402d833c446683f3635cf2c214f4
14 Ne8053bb0e72e40268b88ed8b9d08e51f
15 Nef836736ea554c99b54c2f56ebc1b7d9
16 Nfa80b1a85fe649a3861f90c08c70b185
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author Nda3e0bac4aa241998a0442df2da32c8e
20 schema:citation sg:pub.10.1038/bjc.1996.241
21 sg:pub.10.1038/sj.bjc.6600446
22 sg:pub.10.1038/sj.bjc.6690600
23 https://doi.org/10.1002/1097-0142(19910715)68:2<264::aid-cncr2820680208>3.0.co;2-5
24 https://doi.org/10.1016/0277-5379(85)90172-5
25 https://doi.org/10.1016/0959-8049(93)90175-f
26 https://doi.org/10.1016/s1470-2045(05)70175-3
27 https://doi.org/10.1023/a:1026595525977
28 https://doi.org/10.1093/annonc/4.suppl_2.s21
29 https://doi.org/10.1093/annonc/mdf197
30 https://doi.org/10.1093/annonc/mdi309
31 https://doi.org/10.1093/jnci/92.3.205
32 https://doi.org/10.1093/oxfordjournals.annonc.a058495
33 https://doi.org/10.1093/oxfordjournals.annonc.a059319
34 https://doi.org/10.1159/000086780
35 https://doi.org/10.1159/000094563
36 https://doi.org/10.1159/000227250
37 https://doi.org/10.1200/jco.1997.15.6.2403
38 https://doi.org/10.1200/jco.1999.17.2.585
39 https://doi.org/10.1200/jco.2001.19.10.2679
40 https://doi.org/10.1200/jco.2001.19.15.3447
41 https://doi.org/10.1200/jco.2002.09.029
42 https://doi.org/10.1200/jco.2002.11.149
43 https://doi.org/10.1200/jco.2003.02.098
44 https://doi.org/10.1200/jco.2003.03.022
45 https://doi.org/10.1200/jco.2004.10.112
46 https://doi.org/10.1200/jco.2004.12.082
47 https://doi.org/10.1200/jco.2005.06.023
48 https://doi.org/10.3109/07357909009017560
49 schema:datePublished 2007-03
50 schema:datePublishedReg 2007-03-01
51 schema:description BACKGROUND: PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial. This regimen was subsequently modified in a dose-finding study by increasing dose intensity of cisplatin and epirubicin (both at 30 mg/m2 every 14 days) and of gemcitabine (at 800 mg/m2 every 14 days). Results of a consecutive series treated by dose-intense PEFG regimen are herewith reported. MATERIAL AND METHODS: Dose-intense PEFG was administered to chemotherapy-naive patients with stages III-IV PA, < 75 years, performance status (PS) > 50, till progressive disease or for a maximum of 6 months. RESULTS: Between January 2004 and June 2005, 49 (31 or 63% metastatic) patients, median age 62 years, median PS 80, were treated with dose-intense PEFG. Partial response and stable disease was observed in 24 (49%) and 16 (33%) patients, respectively; 31 patients were progression-free at 6 months (PFS-6 = 63%). Median survival was 10.5 months and 1-year overall survival (OS) was 48% (95% confidence interval: 33-61%). Main grade 3-4 toxicity was: neutropenia in 26% of patients, stomatitis and fatigue in 8%, anaemia, diarrhoea, nausea/vomit in 6%, febrile neutropenia and thrombocytopaenia in 4%, hand-foot syndrome in 2%. CONCLUSION: When compared with 84 patients treated by classical PEFG at the same institution, dose-intense PEFG was not inferior in terms of PFS-6 (63 versus 57%), 1-year OS (48 versus 42%) and response rate (49 versus 49%); it allowed to increase dose intensity for gemcitabine by 32%, for cisplatin and epirubicin by 36% (FU reduced by 3%), to significantly reduce grade 3-4 hematological toxicity (neutropenia: 26 versus 86%; P < 0.00001; thrombocytopaenia: 4 versus 58%; P < 0.00001) and to reduce by one-third the number of outpatient accesses. The new PEFG schedule appears more suitable for clinical use and should be preferred as a basis for further development of therapeutic strategies against pancreatic cancer.
52 schema:genre research_article
53 schema:inLanguage en
54 schema:isAccessibleForFree false
55 schema:isPartOf N5801a2a5b84a434c98b290e97a8adcda
56 N76c8192b1b504c1da494ea714cb97851
57 sg:journal.1088364
58 schema:name Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma
59 schema:pagination 361
60 schema:productId N3087667d14d54bfab956f1076083cf33
61 N54a784e0738644178fb67d0dd98e29db
62 N8a1998201577402399d52203985ca91b
63 Nd12e4444c6f342af9e40bbb6dd298795
64 Neb15338437714c9298b398b00b010dda
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040836963
66 https://doi.org/10.1007/s00280-006-0277-7
67 schema:sdDatePublished 2019-04-11T14:28
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher N898b625219f5487aab182fa28f97c303
70 schema:url http://link.springer.com/10.1007%2Fs00280-006-0277-7
71 sgo:license sg:explorer/license/
72 sgo:sdDataset articles
73 rdf:type schema:ScholarlyArticle
74 N07c948804ea144d2bc0ef1b0f546ffb6 rdf:first sg:person.0613402062.26
75 rdf:rest rdf:nil
76 N3087667d14d54bfab956f1076083cf33 schema:name pubmed_id
77 schema:value 16807732
78 rdf:type schema:PropertyValue
79 N35bc1b10fc4249b7890a360a025d7ab6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Pancreatic Neoplasms
81 rdf:type schema:DefinedTerm
82 N3b8c4fc0d0cd4aa2aaef9187cbfb149d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Adult
84 rdf:type schema:DefinedTerm
85 N4494ff0f18c74dac90bf1f8d1da88352 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Male
87 rdf:type schema:DefinedTerm
88 N4dd4a4262e1d44f785c0c57bc11cad05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Neoplasm Staging
90 rdf:type schema:DefinedTerm
91 N5373967802134d0db31e2d14be533f3c rdf:first sg:person.01210713123.27
92 rdf:rest N71c8deb5f86b4459b035a0eabb3c79ce
93 N54a784e0738644178fb67d0dd98e29db schema:name readcube_id
94 schema:value c2881d6f31213e0428f2a9c92a0a134ef8c85ad6db4e9e21b0490103ad63a28c
95 rdf:type schema:PropertyValue
96 N5801a2a5b84a434c98b290e97a8adcda schema:volumeNumber 59
97 rdf:type schema:PublicationVolume
98 N5b9ed0233be84f34aacc3a95d4353e9b rdf:first sg:person.0736672032.67
99 rdf:rest N9f23428429cd4e778b8c88a6795d41b3
100 N60549f56ff20416086a684d7c21af644 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Middle Aged
102 rdf:type schema:DefinedTerm
103 N700472d67897436ab8f2fe79e19a179f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Humans
105 rdf:type schema:DefinedTerm
106 N71c8deb5f86b4459b035a0eabb3c79ce rdf:first sg:person.0653211100.79
107 rdf:rest Nb41ca114babe43a989de88a3f13091ae
108 N76c8192b1b504c1da494ea714cb97851 schema:issueNumber 3
109 rdf:type schema:PublicationIssue
110 N7d75d175f19645d28da64e8eb2c69326 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Cisplatin
112 rdf:type schema:DefinedTerm
113 N898b625219f5487aab182fa28f97c303 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N8a1998201577402399d52203985ca91b schema:name dimensions_id
116 schema:value pub.1040836963
117 rdf:type schema:PropertyValue
118 N948a80440f7a48969383599720c58afa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Epirubicin
120 rdf:type schema:DefinedTerm
121 N96b40777b6bc46c18db018fe21c9b4b3 rdf:first sg:person.01134654171.43
122 rdf:rest N5b9ed0233be84f34aacc3a95d4353e9b
123 N9f23428429cd4e778b8c88a6795d41b3 rdf:first sg:person.01301141117.22
124 rdf:rest Nc9f03d202a764499b0456010c7111d60
125 Na1ef3444a42247f0900f27af05b6a273 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Fluorouracil
127 rdf:type schema:DefinedTerm
128 Nb41ca114babe43a989de88a3f13091ae rdf:first sg:person.014206563142.61
129 rdf:rest N96b40777b6bc46c18db018fe21c9b4b3
130 Nbc92367c1544482fa38207f0c184da14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Aged
132 rdf:type schema:DefinedTerm
133 Nc9f03d202a764499b0456010c7111d60 rdf:first sg:person.01106712025.46
134 rdf:rest Ndf2cd00a2ce74955ab2a521a4053e969
135 Nd12e4444c6f342af9e40bbb6dd298795 schema:name doi
136 schema:value 10.1007/s00280-006-0277-7
137 rdf:type schema:PropertyValue
138 Nd5b0e4910db64270b901219620839a59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Deoxycytidine
140 rdf:type schema:DefinedTerm
141 Nda3e0bac4aa241998a0442df2da32c8e rdf:first sg:person.01164712517.20
142 rdf:rest N5373967802134d0db31e2d14be533f3c
143 Ndd38beb575484bb0937f7522aeb3b06e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Survival Rate
145 rdf:type schema:DefinedTerm
146 Ndebe402d833c446683f3635cf2c214f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Female
148 rdf:type schema:DefinedTerm
149 Ndf2cd00a2ce74955ab2a521a4053e969 rdf:first sg:person.0635165414.38
150 rdf:rest N07c948804ea144d2bc0ef1b0f546ffb6
151 Ne8053bb0e72e40268b88ed8b9d08e51f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Antineoplastic Combined Chemotherapy Protocols
153 rdf:type schema:DefinedTerm
154 Neb15338437714c9298b398b00b010dda schema:name nlm_unique_id
155 schema:value 7806519
156 rdf:type schema:PropertyValue
157 Nef836736ea554c99b54c2f56ebc1b7d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Dose-Response Relationship, Drug
159 rdf:type schema:DefinedTerm
160 Nfa80b1a85fe649a3861f90c08c70b185 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Adenocarcinoma
162 rdf:type schema:DefinedTerm
163 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
164 schema:name Medical and Health Sciences
165 rdf:type schema:DefinedTerm
166 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
167 schema:name Oncology and Carcinogenesis
168 rdf:type schema:DefinedTerm
169 sg:journal.1088364 schema:issn 0344-5704
170 1432-0843
171 schema:name Cancer Chemotherapy and Pharmacology
172 rdf:type schema:Periodical
173 sg:person.01106712025.46 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
174 schema:familyName Nicoletti
175 schema:givenName R.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106712025.46
177 rdf:type schema:Person
178 sg:person.01134654171.43 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
179 schema:familyName Passoni
180 schema:givenName P.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134654171.43
182 rdf:type schema:Person
183 sg:person.01164712517.20 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
184 schema:familyName Reni
185 schema:givenName M.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164712517.20
187 rdf:type schema:Person
188 sg:person.01210713123.27 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
189 schema:familyName Cereda
190 schema:givenName S.
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210713123.27
192 rdf:type schema:Person
193 sg:person.01301141117.22 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
194 schema:familyName Balzano
195 schema:givenName G.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301141117.22
197 rdf:type schema:Person
198 sg:person.014206563142.61 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
199 schema:familyName Viganò
200 schema:givenName M. G.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014206563142.61
202 rdf:type schema:Person
203 sg:person.0613402062.26 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
204 schema:familyName Di Carlo
205 schema:givenName V.
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0613402062.26
207 rdf:type schema:Person
208 sg:person.0635165414.38 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
209 schema:familyName Staudacher
210 schema:givenName C.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0635165414.38
212 rdf:type schema:Person
213 sg:person.0653211100.79 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
214 schema:familyName Bonetto
215 schema:givenName E.
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653211100.79
217 rdf:type schema:Person
218 sg:person.0736672032.67 schema:affiliation https://www.grid.ac/institutes/grid.18887.3e
219 schema:familyName Zerbi
220 schema:givenName A.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736672032.67
222 rdf:type schema:Person
223 sg:pub.10.1038/bjc.1996.241 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008202113
224 https://doi.org/10.1038/bjc.1996.241
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/sj.bjc.6600446 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036077984
227 https://doi.org/10.1038/sj.bjc.6600446
228 rdf:type schema:CreativeWork
229 sg:pub.10.1038/sj.bjc.6690600 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045839896
230 https://doi.org/10.1038/sj.bjc.6690600
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1002/1097-0142(19910715)68:2<264::aid-cncr2820680208>3.0.co;2-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039599345
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1016/0277-5379(85)90172-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047008979
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1016/0959-8049(93)90175-f schema:sameAs https://app.dimensions.ai/details/publication/pub.1042821579
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1016/s1470-2045(05)70175-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026335507
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1023/a:1026595525977 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056311729
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1093/annonc/4.suppl_2.s21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059393332
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1093/annonc/mdf197 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014876436
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1093/annonc/mdi309 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024868281
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1093/oxfordjournals.annonc.a058495 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082841549
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1093/oxfordjournals.annonc.a059319 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082871349
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1159/000086780 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016938291
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1159/000094563 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018012713
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1159/000227250 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002795994
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1200/jco.1997.15.6.2403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083106816
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1200/jco.1999.17.2.585 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074265658
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1200/jco.2001.19.10.2679 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074814012
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1200/jco.2001.19.15.3447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074857555
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1200/jco.2002.09.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203121
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1200/jco.2002.11.149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203191
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1200/jco.2003.02.098 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203404
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1200/jco.2003.03.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203433
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1200/jco.2004.10.112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020324460
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1200/jco.2004.12.082 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022163283
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1200/jco.2005.06.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048830818
281 rdf:type schema:CreativeWork
282 https://doi.org/10.3109/07357909009017560 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031573606
283 rdf:type schema:CreativeWork
284 https://www.grid.ac/institutes/grid.18887.3e schema:alternateName San Raffaele Hospital
285 schema:name Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy
286 Department of Radiology, San Raffaele Scientific Institute, Milan, Italy
287 Department of Surgery, San Raffaele Scientific Institute, Milan, Italy
288 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...